The Global Market for Novel Peripheral and Neurointerventional Therapeutic Systems Set to Reach $1.5B by 2018 Driven Largely by Explosive Growth in the Drug-Eluting Balloon Market

HUNTINGTON BEACH, Calif., Feb. 19, 2015 /PRNewswire/ -- Life Science Intelligence (LSI), the medtech industry's authority on emerging markets, has reported in its newest analysis that the global market for novel peripheral and neurointerventional therapeutic systems targeting critical limb ischemia (CLI) and acute ischemic stroke (AIS) will grow from $421.7M in 2014 to $1.5B by 2018.  This growth is being driven by the recent introduction of novel and promising revascularization technologies, including peripheral drug-eluting balloon (DEB) angioplasty systems, peripheral drug-eluting stents (DES), and next generation cerebral thrombectomy devices, all of which are intended to remedy major functional deficiencies of existing endovascular therapies and offer efficacious limb and life saving treatment regimens to grossly underserved multimillion CLI and AIS patient caseloads.  In 2014, approximately 153 thousand novel peripheral/cerebral interventions were performed -- LSI is forecasting this number to grow at a 42.4% CAGR reaching 662 thousand procedures by 2018. 

Medical device manufacturers are looking to capitalize on these high growth markets with major players and emerging innovators already competing for share and early-market-entry advantages.  Current suppliers gaining market share include Bard Peripheral Vascular (C.R. Bard), Medtronic, Cook Medical, Cordis, Abbott Vascular, Boston Scientific, Penumbra, Covidien, and Stryker. Other players aiming to establish or consolidate their market presence and maximize corresponding product revenues include Aachen Resonance, Bayer/Medrad, Biosensors International, Cardionovum, Eurocor, iVascular, Acandis, BALT Extrusion, Codman/DePuy, Neuravi, and Phenox, amongst others. 

It is anticipated that by 2018 the U.S. will account for over 50% of the total global market for peripheral DEB, DES and cerebral thrombectomy devices, with the largest Western European states and major Asian states following at a distance, accounting for 23.6% and 21.4% of the market, respectively.  The report provides an in-depth timely analysis of the patient populations, procedures, novel technologies, and competitors that will drive growth in these markets.  Additional details can be found at: http://lifescienceintelligence.com/market-reports-page.php?id=LSI-122014.

About Life Science Intelligence (LSI)®
LSI delivers high-quality market data and competitive intelligence to medical technology executives, entrepreneurs, and investors.  LSI produces the Emerging Medical Technologies (EMT)® Database, hosts EMT Conferences, and provides global market reports and custom research services to the medtech industry. 

Contact:
Life Science Intelligence (LSI)
Scott Pantel, 1-714-847-3540
[email protected]
www.LSintelligence.com

SOURCE Life Science Intelligence

Related Links

http://www.LifeScienceIntelligence.com